en
ar en fr pt es tr

Breast Cancer Prognostic Test

Myriad is a company with it’s registered place in Germany for the , production and distribution of molecular biological systems for diagnostics in the field of oncology and genetic predispositions.

Available In: UAE, Saudi, Bahrian, Qatar, Jordan, Lebanon, Oman, Kuwait, Pakistan,…

Egypt, South Africa.

Show more

Don’t see your country and want to introduce this product in your region? Contact us here.
View products:
ENDOPREDICT® BREAST CANCER PROGNOSTIC TEST

Provides accurate results for patients diagnosed with ER+, HER2- early-stage breast cancer with either node negative or node positive diseases (1-3 nodes).

Request A Quote
EndoPredict is proven to have prognostic power to provide you with results you can trust:
  • helps healthcare professionals guide ER+, HER2- early-stage breast cancer patients toward the appropriate treatment decision.
  • powerful prognostic information for both N0 and N1 patients.
  • demonstrates superior prognostic performance in node-positive disease.
Features:
  • Individualized binary result with chemotherapy benefit
  • Lower cost vs other breast cancer recurrence tests
  • Inclusion of proliferation- and hormone receptor–related genes contributes to accurate assessment of early and late recurrence risk.
  • Better identifies a large percentage of low-risk patients (average of 6% recurrence) - More than 70% of N0 patients, up to 30% of N+ patients
Partner Details
  • Share
  • Copy URL
Categories:
Diagnostics
Tags:
Oncology
www.myriad.com

Complementary Partners 

About Us
Our Partners
Contact Us
EVENTS
Request a quote
NEWS
Divisions

Back to top

Facebook-f Linkedin-in Youtube
©Alliance Global Group (AGBL) All Rights Reserved